Mumbai: A global flight to quality in the aftermath of tariff-driven volatility has widened credit spreads across dollar bonds issued by Indian corporates, leading to a sharp repricing divergence between investment-grade and high-yield bonds in the secondary market. However, following US president (Donald) Trump’s decision to pause reciprocal tariffs for 90 days, while raising Chinese … Read more
Biocon on Thursday said its board has approved to acquire 1.5% equity share capital for Rs 550 crore in Biocon Biologics, from one of its existing investors who decided to exercise the liquidity option, in an all cash deal. Post this purchase, Biocon’s stake in Biocon Biologics will be 90.2%. The purchase is expected to … Read more
Representational image only. | Photo Credit: The Hindu Biocon Limited on October 18 said the U.S. health regulator has classified as ‘official action indicated’ for the manufacturing facility of group firm Biocon Sdn Bhd at Johor, Malaysia following an inspection. The OAI (Official Action Indicated) status may cause delay and/or withholding of pending product approvals … Read more
Biocon’s partner US-based Equillium Inc has expanded its ‘EQUALISE’ study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing. Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said the clinical study for its biologic drug Itolizumab for the possible indication … Read more